Forskning ved Københavns Universitet - Københavns Universitet

Forside

Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. / Andersen, Ellen Sloth; Ruhwald, M; Moessner, B; Christensen, P B; Andersen, O; Eugen-Olsen, J; Weis, N; Weis, N.

I: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, Bind 30, Nr. 6, 2011, s. 761-6.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Andersen, ES, Ruhwald, M, Moessner, B, Christensen, PB, Andersen, O, Eugen-Olsen, J, Weis, N & Weis, N 2011, 'Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1', European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, bind 30, nr. 6, s. 761-6. https://doi.org/10.1007/s10096-010-1149-y, https://doi.org/10.1007/s10096-010-1149-y

APA

Andersen, E. S., Ruhwald, M., Moessner, B., Christensen, P. B., Andersen, O., Eugen-Olsen, J., ... Weis, N. (2011). Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 30(6), 761-6. https://doi.org/10.1007/s10096-010-1149-y, https://doi.org/10.1007/s10096-010-1149-y

Vancouver

Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J o.a. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2011;30(6):761-6. https://doi.org/10.1007/s10096-010-1149-y, https://doi.org/10.1007/s10096-010-1149-y

Author

Andersen, Ellen Sloth ; Ruhwald, M ; Moessner, B ; Christensen, P B ; Andersen, O ; Eugen-Olsen, J ; Weis, N ; Weis, N. / Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. I: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2011 ; Bind 30, Nr. 6. s. 761-6.

Bibtex

@article{8b19951eb3db41fa80f2bda06f79d1be,
title = "Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1",
abstract = "Information about the stage of liver fibrosis is important for managing patients with chronic hepatitis C (CHC). The aim of this study was to evaluate 12 plasma markers for differentiating no/mild liver fibrosis from cirrhosis among patients with CHC genotype 1. Transient elastography was used to assess the stage of fibrosis for the patients included in the study. Forty patients were included (21 cirrhotic). Plasma levels of tumor necrosis factor-a (TNF-a), interleukin 8 (IL-8), interferon-¿ inducible protein-10 (IP-10), monocyte chemotactic protein-1 (MCP-1), soluble urokinase-type plasminogen activator (suPAR), monokine induced by ¿-interferon (MIG), human hepatocyte growth factor (HGF), insulin, interleukin 6 (IL-6), interleukin 1-{\ss} (IL-1{\ss}), leptin, and nerve growth factor (NGF) were analyzed. Concentrations of TNF-a (median 15.0 vs. 25.1 pg/ml, area under the receiver operating characteristic curve [AUC] 0.91), IL-8 (48.7 vs. 103.3 pg/ml, AUC 0.85), IP-10 (176 vs. 566 pg/ml, AUC 0.83), MCP-1 (449 vs. 735 pg/ml, AUC 0.78), suPAR (3.5 vs. 5.2 ng/ml, AUC 0.78), MIG (100 vs. 152 pg/ml, AUC 0.75), and HGF (3.69 vs. 5.58 ng/ml, AUC 0.71) were significantly higher in patients with cirrhosis. In conclusion, several of the investigated markers showed promise for differentiating cirrhosis from no/mild fibrosis among patients with CHC genotype 1.",
author = "Andersen, {Ellen Sloth} and M Ruhwald and B Moessner and Christensen, {P B} and O Andersen and J Eugen-Olsen and N Weis and N Weis",
year = "2011",
doi = "10.1007/s10096-010-1149-y",
language = "English",
volume = "30",
pages = "761--6",
journal = "European Journal of Clinical Microbiology & Infectious Diseases",
issn = "0934-9723",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1

AU - Andersen, Ellen Sloth

AU - Ruhwald, M

AU - Moessner, B

AU - Christensen, P B

AU - Andersen, O

AU - Eugen-Olsen, J

AU - Weis, N

AU - Weis, N

PY - 2011

Y1 - 2011

N2 - Information about the stage of liver fibrosis is important for managing patients with chronic hepatitis C (CHC). The aim of this study was to evaluate 12 plasma markers for differentiating no/mild liver fibrosis from cirrhosis among patients with CHC genotype 1. Transient elastography was used to assess the stage of fibrosis for the patients included in the study. Forty patients were included (21 cirrhotic). Plasma levels of tumor necrosis factor-a (TNF-a), interleukin 8 (IL-8), interferon-¿ inducible protein-10 (IP-10), monocyte chemotactic protein-1 (MCP-1), soluble urokinase-type plasminogen activator (suPAR), monokine induced by ¿-interferon (MIG), human hepatocyte growth factor (HGF), insulin, interleukin 6 (IL-6), interleukin 1-ß (IL-1ß), leptin, and nerve growth factor (NGF) were analyzed. Concentrations of TNF-a (median 15.0 vs. 25.1 pg/ml, area under the receiver operating characteristic curve [AUC] 0.91), IL-8 (48.7 vs. 103.3 pg/ml, AUC 0.85), IP-10 (176 vs. 566 pg/ml, AUC 0.83), MCP-1 (449 vs. 735 pg/ml, AUC 0.78), suPAR (3.5 vs. 5.2 ng/ml, AUC 0.78), MIG (100 vs. 152 pg/ml, AUC 0.75), and HGF (3.69 vs. 5.58 ng/ml, AUC 0.71) were significantly higher in patients with cirrhosis. In conclusion, several of the investigated markers showed promise for differentiating cirrhosis from no/mild fibrosis among patients with CHC genotype 1.

AB - Information about the stage of liver fibrosis is important for managing patients with chronic hepatitis C (CHC). The aim of this study was to evaluate 12 plasma markers for differentiating no/mild liver fibrosis from cirrhosis among patients with CHC genotype 1. Transient elastography was used to assess the stage of fibrosis for the patients included in the study. Forty patients were included (21 cirrhotic). Plasma levels of tumor necrosis factor-a (TNF-a), interleukin 8 (IL-8), interferon-¿ inducible protein-10 (IP-10), monocyte chemotactic protein-1 (MCP-1), soluble urokinase-type plasminogen activator (suPAR), monokine induced by ¿-interferon (MIG), human hepatocyte growth factor (HGF), insulin, interleukin 6 (IL-6), interleukin 1-ß (IL-1ß), leptin, and nerve growth factor (NGF) were analyzed. Concentrations of TNF-a (median 15.0 vs. 25.1 pg/ml, area under the receiver operating characteristic curve [AUC] 0.91), IL-8 (48.7 vs. 103.3 pg/ml, AUC 0.85), IP-10 (176 vs. 566 pg/ml, AUC 0.83), MCP-1 (449 vs. 735 pg/ml, AUC 0.78), suPAR (3.5 vs. 5.2 ng/ml, AUC 0.78), MIG (100 vs. 152 pg/ml, AUC 0.75), and HGF (3.69 vs. 5.58 ng/ml, AUC 0.71) were significantly higher in patients with cirrhosis. In conclusion, several of the investigated markers showed promise for differentiating cirrhosis from no/mild fibrosis among patients with CHC genotype 1.

U2 - 10.1007/s10096-010-1149-y

DO - 10.1007/s10096-010-1149-y

M3 - Journal article

C2 - 21229279

VL - 30

SP - 761

EP - 766

JO - European Journal of Clinical Microbiology & Infectious Diseases

JF - European Journal of Clinical Microbiology & Infectious Diseases

SN - 0934-9723

IS - 6

ER -

ID: 34097620